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Objective: Although aldosterone has been implicated in the pathogenesis of cardiac hypertrophy and heart failure, its cellular mechanism of
action on cardiomyocyte function is not yet completely elucidated. This study was designed to investigate the effect of aldosterone on
calcium channel expression and cardiomyocyte contraction frequency.
Methods: Cultured neonatal rat ventricular cardiomyocytes were stimulated in vitro with 1 Amol/L aldosterone for 24 h. Calcium currents
were then measured with the patch clamp technique, while calcium channel expression was assessed by real-time RT-PCR.
Results: In the present study, we show that aldosterone increases Ca2+ currents by inducing channel expression. Indeed, aldosterone led to a
substantial increase of L- and T-type Ca2+ current amplitudes, and we found a concomitant 55% increase of the mRNA coding for a1C and h2
subunits of cardiac L channels. Although T-type currents were relatively small under control conditions, they increased 4-fold and T channel
a1H isoform expression rose in the same proportion after aldosterone treatment. Because T channels have been implicated in the modulation
of membrane electrical activity, we investigated whether aldosterone affects the beating frequency of isolated cardiomyocytes. In fact,
aldosterone dose-dependently increased the spontaneous beating frequency more than 4-fold. This effect of aldosterone was prevented by
actinomycin D and spironolactone and reduced by RU486, suggesting a mixed mineralocorticoid/glucocorticoid receptor-dependent
transcriptional mechanism. Moreover, inhibition of T currents with Ni2+ or mibefradil significantly reduced beating frequency towards
control values, while conditions affecting L-type currents completely blocked contractions.
Conclusion: Aldosterone modulates the expression of cardiac voltage-operated Ca2+ channels and accelerates beating in cultured neonatal
rat ventricular myocytes. This chronotropic action of aldosterone appears to be linked to increased T channel activity and could contribute to
the deleterious effect of an excess of this steroid in vivo on cardiac function.
D 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Renin angiotensin system; Ca-channel; Gene expression; Contractile function; Ventricular arrhythmias
1. Introduction spironolactone, an aldosterone antagonist, this hormone hasSince the publication of the RALES clinical trial [1]
demonstrating the beneficial effect on the cardiac function of0008-6363/$ - see front matter D 2005 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2005.05.009
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E-mail address: michel.rossier@hcuge.ch (M.F. Rossier).been rapidly considered as a major cardiovascular risk factor.
Aldosterone is clearly involved in the development of the
cardiac hypertrophy and fibrosis associated with congestive
heart failure, and its action appears independent of a rise of
the blood pressure [2–4]. However, the pathophysiological
mechanisms of aldosterone action remain largely unknown.
The high mortality associated with congestive heart
failure is due to higher incidence of ventricular arrhythmias.67 (2005) 216 – 224ed by Elsevier B.V. All rights reserved.
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has been recently observed in patients treated with
spironolactone, strongly suggesting that aldosterone may
contribute to the incidence of ventricular arrhythmia [5].
Among the various electrical mechanisms leading to
arrhythmia, T-type calcium channel dysregulation could be
important because of the function of these channels in heart
pacemaker [6–8].
Low-threshold, voltage-operated T-type Ca2+ channels
appear as particularly interesting candidates for playing a
causal role in various pathologies [9]. Their recent cloning
and molecular characterization revealed that these channels
have evolved apart from L-type and other neuronal Ca2+
channels, suggesting a particular role in the cell, and
therefore specific consequences or ‘‘channelopathies’’ in
case of dysfunction. Three genes code for the various T
channel isoforms (a1G, a1H and a1I) that are apparently all
composed of a single, large a1 subunit [10]. Currents
generated by a1G and a1H channels are nearly identical, but
the higher sensitivity of a1H to nickel (IC50=10 Amol/L vs.
300 Amol/L for a1G) represents a practical mean for
discriminating between these channels [11].
One of the first physiological functions proposed for T
channels was a support for a pacemaker current [12],
because they activate at very negative voltages and resulting
calcium entry leads to membrane depolarization. This role is
well recognized in the heart, where nickel exerts a negative
chronotropic effect [6,7].
Changes in their expression levels have been observed
during the development of various organs, suggesting an
important role for Tchannels at specific stages of the fetal life
[13,14]. Particularly, in most mammalian species, T currents
are robustly expressed in embryonic heart, in both atrial and
ventricular myocytes, but are absent or much reduced in
postnatal ventricular myocytes [15,16]. A quantitative
analysis of the rat a1 subunit transcripts revealed that,
whereas a1C (L-type channel) does not vary in expression
during the development and remains 10–100 times more
abundant than other channels, the levels of a1H mRNA are
high in embryonic tissue and at 3 weeks postnatal, but
become undetectable at 5 weeks [17]. In contrast, the levels of
a1G, already present in fetal mouse myocardium [18], are
maintained in rats during the postnatal period, as well as in
adults [17]. Similar observations were made in human heart,
where mRNA coding for both a1G [19] and a1H [20] have
been identified but with significant decreases of a1H during
development [21]. No T currents were detected in human
adult ventricular or atrial cells [22,23].
In the present study, we hypothesized that aldosterone
excess induces a re-expression of T-type calcium channels
in the heart. This hypothesis was supported by several
arguments: (1) aldosterone has been shown in vitro to
increase the expression of T-type channels in adrenal cells
[24] and of L-type channels in cardiomyocytes [25], but the
induction of T channels in cardiomyocytes had not been
evaluated yet; (2) like other ‘‘fetal genes’’ re-expressed uponventricular remodeling, T channels decrease during develop-
ment but re-appear in ventricular cells from hypertrophied
rat hearts or after infarction [26,27]; (3) mibefradil, an
inhibitor of T channels, exerts a beneficial action on the
cardiac function [28,29] and T channel blockade results in
lower pacemaker activity of the sinus node [30]; and finally
(4) mineralocorticoid antagonists improve tachycardia,
arrhythmias and ventricular fibrillation in congestive heart
failure [5,31], while mineralocorticoid receptor over-expres-
sion leads to tachycardia [32].2. Experimental procedures
2.1. Cell culture
Neonatal cardiac cells were isolated from 1- to 2-day-old
Wistar rats ventricles by digestion with low trypsin–EDTA
and type 2 collagenase, as previously described [33].
Animals were killed in conformity with the Guide for the
Care and Use of Laboratory Animals published by the NIH
(Publication No. 85-23). Importantly, using high trypsin
concentrations during cell preparation appeared deleterious
for T currents, possibly explaining earlier negative results
[34]. Freshly isolated cells were seeded in 90-mm Petri
dishes to allow selective adhesion of cardiac fibroblasts
[35]. Thereafter, cardiomyocytes were decanted from the
plates and seeded in Petri dishes or in six-well culture plates.
2.2. Cell contraction frequency
Cardiomyocytes were seeded in laminin-coated Petri
dishes. Spontaneously contracting cell monolayers were
incubated for the indicated times with the appropriate
concentration of agonist or vehicle in serum-free DMEM. Cell
beating frequency was determined by counting the number of
monolayer contractions per time unit under microscope.
In a few preparations, images of contracting cell
monolayers were recorded on an Axiovert S100TV micro-
scope, using an 100 1.3 NA oil immersion objective (Carl
Zeiss AG). Image acquisition (30 images/s) and analysis
were performed with the Metamorph/Metafluor 4.1.2 soft-
ware. Contractions were followed in real time by analyzing
the variations of the mean light intensity within a small
region arbitrarily fixed at the edge of single cells.
2.3. Electrophysiological recordings
Cardiomyocytes were plated for electrophysiological
recordings after enrichment on a discontinuous (40.5%
and 58.5% layers) Percoll (Amersham) density gradient.
Patch-clamp recordings were performed in the whole-cell
configuration using an Axopatch 1D amplifier (Axon
Instruments). Currents were filtered at 1–2 kHz, digitized
and sampled at 5 kHz using a TL-1-125 interface and
pClamp V.6 software (Axon Instruments). The bath solution
N. Laleve´e et al. / Cardiovascular Research 67 (2005) 216–224218contained (in mmol/L) 125 N-methyl-glucamine, 5 4-
aminopyridine, 20 tetraethylammonium chloride, 2 CaCl2,
2 MgCl2 and 10 d-glucose and was buffered to pH 7.4 with
10 HEPES. The patch pipettes were filled with solution
containing (in mmol/L) 130 CsCl, 10 EGTA, 3 Mg-ATP, 0.4
Li-GTP; pH was adjusted to 7.2 with 25 HEPES.
In order to discriminate between T- and L-type currents, a
2-pulse voltage protocol was employed [15].
2.4. Total RNA isolation and mRNA quantification
Total RNA from cardiomyocytes was extracted using the
NucleoSpin\ RNA II kit (Macherey-Nagel) and its integrity
was analyzed by electrophoresis with a chip-based RNA
analysis system (Agilent Technologies).
Total RNA (400 ng) was reverse-transcribed using the
Taqman Gold RT-PCR kit (Applied Biosystems) and
random hexamers. The relative abundance of channel
subunit mRNAs was assessed by Taqman qPCR and
cyclophilin A was used to normalize data. Reactions in
Taqman Universal Master Mix (Applied Biosystems) were
performed using an iCycler iQ detection system (Bio-Rad).
The sequence and concentration of specific primers and
Taqman probes are indicated in Table 1 and were the same
as those previously described elsewhere [36].
2.5. Drugs
Aldosterone, corticosterone, spironolactone, RU486,
actinomycin D, NiCl2, nitrendipine and laminin were
purchased from Sigma. Mibefradil was from Roche.
2.6. Statistics
Results are expressed as the meansTS.E.M. unless stated
otherwise. The statistical significance of changes was
analyzed by 2-tail paired or unpaired Student’s t-tests.Table 1
Primers and probes used in real-time RT-PCR assays
Gene Oligonucleotide sequence
a1C fw: 5V-AGCAACTTCCCTCAGACGTTTG
rev: 5V-GCTTCTCATGGGACGGTGAT
probe: 5V-CAACAAGACAGGGAACAACCAAGC
h2 fw: 5V-CCGACTATCTGGAGGCGTACTG
rev: 5V-GTGGCTAAAGTCCGGCTAAGG
probe: 5V-ACCCACCCTCCCAGCAGTAACCTCC
a1G fw: 5V-ACGCTGAGTCTCTCTGGTTTGTC
rev: 5V-TGCTTACGTGGGACTTTTCAGA
probe: 5V-CGGGTGCAGATCCTACGTCCGC
a1H fw: 5V-GGCGAAGAAGGCAAAGATGA
rev: 5V-GCGTGACACTGGGCATGTT
probe: 5V-AGGCCTCCAAGATGCTGCAACGTTC
cyclo fw: 5V-TGTGCCAGGGTGGTGACTT
rev: 5V-TCAAATTTCTCTCCGTAGATGGACTT
probe: 5V-ACACGCCATAATGGCACTGGTGG
Abbreviations: fw, forward primer; rev, reverse primer; probe, 6-carboxy-fluores
cyclophilin A. Sequences of oligonucleotides were obtained from the indicated re3. Results
3.1. Aldosterone increases T-type and L-type calcium
currents in neonatal rat cardiomyocytes
Calcium currents were elicited in cultured neonatal rat
ventricular cardiomyocytes by 200-ms step depolarization
of the cells from a holding potential of 100 mV. As
shown in Fig. 1A, exposure of the cells for 24 h to 1
Amol/L aldosterone markedly increased the size of the
inward currents. Although aldosterone had no effect on
cell capacitance (25.7T3.8 pF after aldosterone treatment
vs. 28.3T2.8 pF in control cells, meanTS.D., n =14),
current amplitudes were normalized by the cell capacitance
(in pA/pF) to allow comparisons independently of the
individual cell size variability. Aldosterone did not affect
the kinetics of the current activation and inactivation, nor
their steady-state inactivation (data not shown). The
analysis of the current–voltage relationship revealed that
the amplitude of the peak current was increased by
aldosterone at any voltage between  50 and + 50 mV
but aldosterone response appeared proportionally more
important at negative potentials (Fig. 1B). This shift of the
IV-curve towards negative voltages was obvious when
expressing the aldosterone-induced current as the current
ratio between treated and untreated cells (Fig. 1C). A peak
of aldosterone response was clearly revealed around  40
mV, where low-threshold T-type currents have the highest
amplitude.
Low Ni2+ concentrations are known to preferentially
inhibit T-type channels (a1H isoform), while higher con-
centrations, within the millimolar range, affect both T- and
L-type currents. We found that aldosterone-treated cells
responded to low Ni2+ more extensively at negative voltages
than at more depolarized voltages (Fig. 1D,E). Indeed,
approximately 70% of the current elicited at  30 mV was
suppressed by 50 Amol/L Ni2+, while less than 25% of theConc. (nmol/L) Ref.
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Fig. 1. Aldosterone increases low-threshold calcium currents in neonate rat ventricular cardiomyocytes. (A) Typical Ca2+ currents elicited by step
depolarization from a holding potential of  100 mV were recorded in an untreated cell (Ctrl) and in a cell exposed for 24 h to 1 Amol/L aldosterone (Aldo). (B)
Voltage–current relationship in control and aldosterone-treated cells. Data are the meanTS.E.M. from five and seven independent recordings for control and
treated cells, respectively. (C) The aldosterone-induced current, determined at each voltage from data illustrated in panel B, was expressed in ratio of the
corresponding control current. (D) Effect of low (50 Amol/L) and high (1 mmol/L) Ni2+ concentrations on calcium currents in an aldosterone-treated cell (1
Amol/L for 24 h). Currents were recorded before (Aldo) and a few minutes after the addition of Ni2+. (E) Same data as in panel D, but expressed as the
percentage of current inhibition induced by Ni2+. (F) The same protocol as described for panel B has been applied to cardiomyocytes isolated from heart atria
(n =5 and 7 for Aldo and Ctrl conditions, respectively).
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firming that low Ni2+ concentrations can discriminate
between low- and high-threshold currents. At 1 mmol/L,
Ni2+ inhibited most of the current at any tested voltage.
Interestingly, when cardiomyocytes were prepared from
the heart atrium instead of the ventricle, no effect of
aldosterone was observed (Fig. 1F).
To determine the relative effect of aldosterone on T- and
L-type channels, we have used a 2-pulse activation protocol.
As previously published [15], the current elicited at  30
mV can be considered as almost exclusively due to T
channel activation, while high-threshold L channels are
mainly responsible for the current recorded during the
second pulse at + 10 mV (Fig. 2A). In untreated cells, the
amplitude of the low-threshold T-type current was much
lower than that of L current (Fig. 2B,C). Nevertheless, after
24 h treatment with 1 Amol/L aldosterone, T currentamplitude increased to 420%, while L current only rose to
190%.
3.2. Modulation of calcium channel expression by
aldosterone
Because the aldosterone-induced increase of current
amplitudes occurred without modification of other electro-
physiological properties, we suspected that this change
resulted from a modulation of channel expression. The
levels of mRNA coding for the various calcium channel
isoforms expressed in cardiomyocytes have been therefore
assessed by real-time RT-PCR (Fig. 3). Aldosterone (1
Amol/L for 24 h) significantly raised by approximately 60%
the levels of mRNA coding for a1C and h2, the major L
channel isoform in the heart and its principal ancillary
subunit, respectively. The T channel response to aldosterone
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Fig. 3. Aldosterone induces the expression of calcium channel subunits in
ventricular cardiomyocytes. Cells were stimulated for 24 h with 1 Amol/L
aldosterone (Aldo) in the absence or in the presence of spironolactone
(Spiro, 10 Amol/L). a1C, h2, a1G and a1H mRNA levels were determined by
quantitative RT-PCR and normalized to cyclophilin A (cyclo) mRNA. By
comparing real-time curves (CT values), a1G mRNA levels were estimated
to be approximately twice those of a1H in control cells, while the levels of
a1C and h2 mRNA amounted to 30 times those of a1H. Experiments were
performed 4–7 times and results are expressed as a percentage of the
control (Ctrl). *P <0.05 and ***P <0.001 compared to control values.
‘‘P <0.01 compared to aldosterone values.
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Fig. 2. Differential effect of aldosterone treatment on low- and high-
threshold calcium currents. (A) Low-threshold (T-type) and high-threshold
(L-type) Ca2+ channels were separately activated with a two-pulse protocol.
Holding potential was 100 mV, the low step to 30 mVand the high step
to +10 mV. The black dot shows the current recorded from a representative
control cell and the white dot from a cell treated for 24 h with 1 Amol/L
aldosterone. (B, C) Low-threshold (B) and high-threshold (C) current
amplitudes determined in cells treated as indicated below (n =7).
N. Laleve´e et al. / Cardiovascular Research 67 (2005) 216–224220was clearly isoform-dependent, with a much larger increase
(up to 410%) in the expression of a1H, while the small rise
of a1G (to 130%) did not reach statistical significance. These
inductions of channel expression were in the same order of
magnitude as the increase observed for the corresponding
currents.
Spironolactone, a mineralocorticoid receptor (MR)
antagonist, at 10 Amol/L, tended to prevent in each case
aldosterone action. The effect of spironolactone was only
significant for a1H, for which approximately 70% of the
raise was prevented. This observation suggests that the
transcriptional response to aldosterone is mediated, at least
in part, by the MR.
3.3. Acceleration of cardiomyocyte beatings by aldosterone
Neonatal rat cardiomyocytes maintained in primary
culture have the property to spontaneously and repeatedly
contract in Petri dishes. Untreated control cells contracted at
a slow basal frequency, with occasional transient accel-
erations (Fig. 4A, left panel), while treatment of the same
cells for 24 h with 1 Amol/L aldosterone markedly
accelerated these in vitro beatings (Fig. 4A, right panel).
The reproducibility of the basal contractions from one
preparation to the other was markedly improved in the
presence of laminin, which was systematically used as a
substrate for the cell culture in the following experiments.
Under these conditions, the mean basal beating frequency in
control cells was 61T9 events/min (n =18 preparations).Basal Aldo 1µmol/L
1 min 1 min
A
0 1 100 1000
0
100
200
300
400
B
e
a
ti
n
g
 f
re
q
u
e
n
cy
(%
 o
f 
C
tr
l)
Aldosterone (nmol/L)
**
**
**
10
B
e
a
ti
n
g
 f
re
q
u
e
n
cy
(%
 o
f 
C
tr
l)
B
Fig. 4. Aldosterone increases the contraction frequency of cardiomyocytes
in a concentration-dependent manner. (A) Contraction frequency was
followed in real time by analyzing images of cells treated (Aldo) or not
(Ctrl) with 1 Amol/L aldosterone for 24 h. (B) Monolayer contractions were
counted under a microscope and expressed as a percentage of the beating
frequency of non-treated cells. Experiments were performed 3 times.
**P <0.01 and *P <0.05 compared to control values.
1 10 100 1000 10000
0
20
40
60
80
100
N
o
rm
a
liz
e
d
 f
re
q
u
e
n
cy
(%
)
NiCl2 ( mol/L)
Ctrl
Aldo * * *
* *
*
100 200 300 400
0
200
400
600
800
Ctrl
B 1000
1
10
100
1000
b
e
a
ti
n
g
 f
re
q
u
e
n
cy
(%
 o
f 
C
tr
l)
 1H / cyclo mRNA  (% of Ctrl)
40
60
80
100
Ctrl
*
*
Aldo
a
liz
e
d
 f
re
q
u
e
n
cy
(%
)
C
N
o
rm
a
liz
e
d
 f
re
q
u
e
n
cy
(%
)
N
o
rm
a
liz
e
d
 f
re
q
u
e
n
cy
(%
)
µ
A
B
b
e
a
ti
n
g
 f
re
q
u
e
n
cy
(%
 o
f 
C
tr
l)
b
e
a
ti
n
g
 f
re
q
u
e
n
cy
(%
 o
f 
C
tr
l)
α
a
liz
e
d
 f
re
q
u
e
n
cy
(%
)
a
liz
e
d
 f
re
q
u
e
n
cy
(%
)
N. Laleve´e et al. / Cardiovascular Research 67 (2005) 216–224 221As shown in Fig. 4B, aldosterone treatment for 24 h
induced a concentration-dependent increase in the beating
frequency. A significant 50% raise of the frequency was
already observed at 1 nmol/L aldosterone, a concentration
close to the MR EC50 (0.1 nmol/L); however, the fact that
further increase persists at much higher concentrations (1
Amol/L) suggests that additional receptors could mediate the
aldosterone effect, including the glucocorticoid receptor
(GR), which is known to be activated by aldosterone with an
EC50>1 Amol/L [37]. In order to determine the mechanism
of the aldosterone chronotropic action, the effect of several
drugs was tested.
As shown in Fig. 5, 24 h stimulation with 1 Amol/L
aldosterone significantly increased the beating frequency of
cardiomyocytes to 475% of the basal level (n =18). This
response was prevented when actinomycin D was added
simultaneously with aldosterone (n =3), demonstrating that
a transcriptional mechanism is indeed necessary, and
excluding a nongenomic action of the hormone [38].
Concerning the specificity of the receptor involved, we
found that spironolactone completely abolished the hor-
mone-induced increase in beating frequency, while a 50%
reduction of the response was observed in the presence of
the GR antagonist RU486. However, the basal frequency
was also markedly affected by this drug (by 36%,
p <0.005, n =5), and a significant response to aldosterone,
corresponding to a 4-fold increase in beating rate, was
maintained even in the absence of a functional GR.
Moreover, corticosterone, the main glucocorticoid in rats,Ctrl Ni2+ nitr
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aldosterone (Aldo, open bars). Transcription, MR activity, GR activity and
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Amol/L, 30 min), respectively. Monolayer contractions were counted under
a microscope and expressed as a percentage of the basal beating frequency
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values obtained in control, aldosterone-stimulated cells (Ctrl/Aldo).
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Fig. 6. T-type calcium channel activity regulates the beating frequency of
cardiomyocytes. (A) Correlation between aldosterone-induced a1H channel
expression and beating frequency was established by comparing both
responses to various aldosterone concentrations (indicated in nmol/L next
to symbols). The responses to 1000 nmol/L corticosterone (Kendall’s
compound B) are also illustrated (filled symbol). (B, C) Calcium channel
activity was inhibited with increasing concentrations of nickel (B) or
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cells. Cell monolayer contractions were counted under a microscope 30 min
after the addition of the calcium channel inhibitor and results were
expressed as a percentage of the beating frequency determined just before
inhibitor addition. Experiments were performed 3 times and IC50 values
were obtained after curve fitting according to a 4-parameter logistic model
(or the addition of 2 such models in the case of Ni2+ inhibition in
aldosterone-treated cells), using the non-linear curve fit option of Origini
V 6.0. *P <0.05 compared to the corresponding values in the absence of
inhibitor.at 1 Amol/L partially mimicked the response to aldosterone
on both a1H expression and contraction frequency (Fig.
6A), indicating that GR activation can also induce the
same responses.
Our results therefore indicate that aldosterone increases
the beating frequency in cardiomyocytes probably via a
mixed MR/GR-dependent mechanism.
N. Laleve´e et al. / Cardiovascular Research 67 (2005) 216–2242223.4. Role of T-type calcium channels in the modulation of
the beating frequency
We hypothesized that, because of their particular electro-
physiological properties, low-threshold T-type calcium
channels could be responsible for the modulation of the
beating frequency. In agreement with our hypothesis, the
expression of a1H in response to aldosterone was also
concentration-dependent and correlated with the beating rate
(Fig. 6A). To formally demonstrate the involvement of T
channels, we reduced pharmacologically their activity after
aldosterone has induced their expression. As shown in Fig.
5, low nickel concentrations (100 Amol/L), which preferen-
tially affect a1H channels, reduced by 50% the response to
aldosterone, but, importantly, without affecting the basal
frequency (measured in untreated cells). Because L channels
are expressed at much higher levels than T channels in
neonate rat cardiomyocytes, we also tested the consequence
of specifically inhibiting L currents. In contrast to nickel, the
L-type channel antagonist nitrendipine (1 Amol/L) markedly
reduced the beating frequency in both aldosterone-treated
and untreated cells, and even completely stopped the
contractions in many cases.
The role of T channels on the beating frequency was
further investigated using increasing concentrations of Ni2+
and mibefradil, two inhibitors of these channels (Fig. 6). A
concentration–inhibition curve by Ni2+ is shown in Fig. 6B,
where the measured frequencies were normalized to the
frequency determined in corresponding cells without inhib-
itors. In naı¨ve (Ctrl) cells, expressing low levels of T
channels, a significant reduction of the beating frequency
was observed only at concentrations of Ni2+ above 200
Amol/L, concentrations known to also affect a1G and L-type
channels [11,9]. In contrast, after aldosterone treatment (and
T channel expression) Ni2+ action appeared clearly biphasic,
with a first step between 10 and 100 Amol/L, where a1H are
preferentially inhibited, followed by a second phase leading
finally to complete contraction arrest.
A change of cell sensitivity to mibefradil was also
observed after cardiomyocyte treatment with aldosterone
(Fig. 6C). Indeed, the IC50 for the mibefradil inhibition was
shifted from 480 nmol/L in control cells down to 360 nmol/
L in aldosterone-treated cells. In contrast to Ni2+ action, no
formal biphasic action of mibefradil could be observed
probably because of the poorer ability of mibefradil for
discriminating between T and L channels, and its tendency
of blocking a1G somewhat better than a1H [9].4. Discussion
In the present study, we have demonstrated that, in
cultured neonate rat ventricular cardiomyocytes, aldoster-
one induces the functional expression of a1H, a T-type
calcium channel, resulting in a marked acceleration of
spontaneous cell contractions. Importantly, these effects ofaldosterone appeared within 24 h, before any sign of cell
hypertrophy.
A modulation of the activity of calcium channels
through their expression has been demonstrated in various
cell types. A change in the expression of a specific channel
isoform, systematically linked to a given pathology, is
suggestive of a role for this channel in the pathophysio-
logical mechanism of the disease. For example, in adult rat
cardiomyocytes, a1C L-type calcium channel over-expres-
sion has been proposed to directly participate to the
electrical remodeling occurring before the development of
cardiac hypertrophy and resulting in the increase of the
action potential duration, reflected by a longer QT interval
on the electrocardiogram [39].
T-type channels have been also proposed to be involved
in cardiac pathologies. Macroscopic T-type currents, that are
almost undetectable in control adult animals, are re-
expressed in left ventricular cardiomyocytes of both cats
[40] and rats [27] when cardiac hypertrophy is experimen-
tally induced by aortic stenosis. Similarly, re-expression of
T-type channels after myocardial infarction or exposure to
growth hormone-secreting tumors has been clearly demon-
strated in remodeled rat left ventricle, even before the
appearance of hypertrophy [41,42].
Left ventricular hypertrophy is an adaptive response that
enables the heart to maintain cardiac function. However,
cardiac hypertrophy is associated with sudden death due to
arrhythmias or other events of cardiac origin [43]. The
unique properties of T-type channels, particularly their low
threshold of activation, makes them particularly prone to
modify electrophysiological characteristics of the cells in
which they are expressed. Thus, not surprisingly, a causative
role for T channels has been proposed for explaining
calcium overload and arrhythmias occurring in a genetically
determined cardiomyopathic Syrian hamster strain express-
ing higher T currents in their myocytes [44].
In our study, the rate of ‘‘beating’’ correlated to a1H
expression and the acceleration induced by aldosterone was
reduced by inhibition of T-type Ca2+ channels. In contrast,
affecting L-type channel activity led to severe contractile
dysfunctions, confirming the crucial role of these channels
in triggering the excitation–contraction coupling. T chan-
nels, on the other hand, affect the frequency of action
potentials. Indeed, because of their low threshold of
activation, T channels activate early during the phase
between two contractions, before the onset of the next
action potential. The resulting inward Ca2+ current is too
small for triggering Ca2+ release from the stores [8], but
sufficient for efficiently depolarizing the cell. The voltage
threshold for the next action potential is then reached more
rapidly under these conditions.
In the whole heart, pacemaker cells from the sino-atrial
node normally control the rate of cardiac contractions by
imposing their own frequency to ventricular cardiomyo-
cytes. This control is profoundly disturbed if ventricular
cells activate too early, before receiving the signal from the
N. Laleve´e et al. / Cardiovascular Research 67 (2005) 216–224 223‘‘conductor’’, this situation favoring the occurrence of
arrhythmias.
Although much caution is necessary when extrapolating
observations performed in vitro, with a particular cell
model, to in vivo pathological situations, our results
nevertheless suggest a new possible molecular mechanism
for explaining the high incidence of ventricular arrhythmias
associated with hyperaldosteronism. As previously men-
tioned, T channel over-expression and beating acceleration
occurred relatively early, after only 24 h exposure to
aldosterone and without any change in the cell size. This
fast response suggests that calcium channel over-expression
could be an early event in the development of cardiac
pathologies involving mineralocorticoids and could orches-
trate secondary modifications occurring later within the
cells.
Interestingly, no response to aldosterone was observed in
atrial cells. The lower sensitivity to aldosterone of atrial
cells as compared to ventricular cells requires further
investigation to discriminate between several possible
explanations, such as differential expression of steroid
receptors, cellular modulators or channel isoforms; however,
based on our results, we would predict that mineralocorti-
coid antagonists should be more efficient to prevent
ventricular arrhythmias than atrial fibrillation, even if T
channels appear to be clearly involved in the latter
pathology [45].
Both a1G and a1H isoforms could a priori be responsible
for modulating the cell beating in vitro, because these two T
channel subtypes share very similar electrophysiological
properties. A role for a1G is indeed supported by the
relatively steeper reduction of beating frequency observed in
control cells (where a1G probably predominates) when
increasing Ni2+ concentration from 200 to 500 Amol/L, as
compared to the inhibition observed at the same Ni2+
concentrations in aldosterone-treated cells (Fig. 6B). How-
ever, only the a1H isoform is induced by the hormone and
selective inhibition of this isoform with low Ni2+ concen-
trations [11] were sufficient to normalize the beating rate. It
is therefore conceivable that, although both a1G and a1H
modulate the beating rate under basal conditions, a1H is
principally responsible for the chronotropic response to
aldosterone.
A possible action of glucocorticoids on the expression of
T channels and the modulation of beating frequency has
been also addressed in the present study. This was
particularly relevant in these cells, because glucocorticoids
are classically considered as exerting a protective action on
the cardiac function, but can mimic mineralocorticoids
under particular conditions [46]. We observed a marked
reduction of the aldosterone-induced acceleration of beat-
ings in the presence of RU486 and we found that cortico-
sterone could mimic aldosterone on both beating frequency
and a1H channel expression. Therefore, we cannot exclude
that aldosterone, at least at micromolar concentrations, also
exerts its action through the glucocorticoid receptor.Because of the partial overlap between the mineralocorti-
coid and the glucocorticoid signaling, further investigation
is required for clearly determining the relative contribution
of MR and GR to the control of T channel expression, and
therefore for understanding how glucocorticoids can exert in
vivo their protective action on the heart [46].
Because T channel knock out mice are available [47],
these animals will represent a valuable model for demon-
strating in vivo the exquisite relationship existing between
aldosterone and these channels. However, it is already
intriguing to realize that T channels appear highly re-
expressed under various pathological situations. This
observation is reminiscent of the re-expression of fetal
genes observed during the evolution of several diseases, like
cardiac hypertrophy or cancer [48]. The apparent associa-
tion between T channel expression and the beating
frequency of isolated cardiomyocytes suggests that aldos-
terone-induced ventricular arrhythmias could be improved
by pharmacologically decreasing the activity of T-type
channels. Hopefully, new findings on molecular properties
and pathophysiological functions of this particular class of
calcium channels will help to target them with specific
pharmacological drugs in order to improve disorders
directly linked to a dysregulation of these channels.Acknowledgements
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